Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swedish biotech company Axelar has announced the initiation of a Phase I/II study of AXL1717, an oral insulin-like growth factor 1 receptor pathway inhibitor, in patients with brain tumours in the US.
Subscribe to our email newsletter
The study designed to assess the investigational drug AXL1717 in patients with relapsed or progressive malignant astrocytomas (glioblastoma and anaplastic astrocytoma) is conducted at the Rush University Medical Center in Chicago.
Voices Against Brain Cancer and Gateway for Cancer Research is also supporting the investigator sponsored study.
Axelar CEO Dr. Carl Harald Janson said, "Preclinical data supports treatment with AXL1717 in patients with astrocytomas and we now look forward to follow this important clinical study, since treatment for astrocytomas remains very challenging and new advances are necessary to improve clinical outcome."
At present, Axelar,a Karolinska Development AB portfolio company, is conducting AXL1717 Phase II trial in patients with non-small cell lung cancer.
The tolerability and efficacy profile of the investigational compound was established in Phase I/II trial conducted in 49 patients.